Abstract
Patient-specific allergen-specific subcutaneous immunotherapy (SCIT) has been used as a disease modifying treatment for type 1 IgE mediated allergy to inhalants for > 100 years. Traditionally, the extracts used for a treatment set have been “mixed” under the supervision of allergists in their clinics. Until 2008, there were no specific requirements for mixing procedures. Allergenic extracts are classified as biologics by the U.S. Food and Drug Administration (FDA) and are subject to the biologics license application requirements. One of the conditions is that it must be prepared in accordance with U.S. Pharmacopeia (USP) Chapter <797>, which was first published in 2008. What allergists have always considered “mixing” of allergen extracts is considered “compounding” by the FDA and other state and federal regulatory agencies. A revision of USP Chapter <797> was proposed after a series of “never events,” including deaths, from compounded products. No reports of infections from SCIT have ever been reported. “Allergy” (ACAAI, AAAAI, AAOA, and other stakeholders) worked cooperatively with the USP Compounding Expert Committee to develop Section 21. “Compounding Allergenic Extracts” of what is expected to be accepted as the next version of USP Chapter <797> in mid 2022.
Publisher
Oceanside Publications Inc.
Subject
Pulmonary and Respiratory Medicine,General Medicine,Immunology and Allergy
Reference19 articles.
1. Allergen immunotherapy: a centenary celebration;Durham;World Allergy Organ J,2011
2. A brief history of allergen immunotherapy;Finegold;Allergy Asthma Proc,2022
3. The United States Pharmacopeial Convention;<797> Pharmaceutical Compounding—Sterile Preparations,2007
4. United States Pharmacopeial Convention: Respecting the past, moving confidently into the future;Tirumalai
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献